Announced Wed, 5 Aug · 19:57 IST
Aurobindo Pharma Q1FY27 Results: Revenue up 16.3%, Net Profit up 25.2%
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.7%1-day move
₹1615.00
prior close
₹1625.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.6-1.2-1.0-2.1+2.7+2.0+2.4+3.0+3.0+0.8————
Up moveDown movePending
AI summary
Aurobindo Pharma Q1FY27: Revenue ₹9,150 Cr (up 16.3% YoY), Operating EBITDA ₹1,924 Cr (up 20%, margin 21%), Net Profit ₹1,032 Cr (up 25.2%), EPS ₹17.86. Strong growth across US (+8.1%), Europe (+25.6%), Growth Markets (+37.7%). 10 US approvals and launches. FCF US$98 mn, net cash US$42 mn after Lannett acquisition ($247M) and buyback ($85M). CuraTeQ biosimilars filed Denosumab with EMA, entered LATAM. TheraNym biologics CMO Unit 1 inaugurated.
Likely market impact
Strong all-round performance with revenue, EBITDA, and profit growth. Margin expansion and biosimilar pipeline progress signal sustained growth momentum.